PE20170128A1 - Compuestos para tratar atrofia muscular espinal - Google Patents
Compuestos para tratar atrofia muscular espinalInfo
- Publication number
- PE20170128A1 PE20170128A1 PE2016002128A PE2016002128A PE20170128A1 PE 20170128 A1 PE20170128 A1 PE 20170128A1 PE 2016002128 A PE2016002128 A PE 2016002128A PE 2016002128 A PE2016002128 A PE 2016002128A PE 20170128 A1 PE20170128 A1 PE 20170128A1
- Authority
- PE
- Peru
- Prior art keywords
- compounds
- muscular atrophy
- alkyl
- spinal muscular
- methylimidazo
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se refiere a compuestos de formula (I) y sales farmaceuticamente aceptables de los mismos, donde: A es N-heterocicloalquilo, NR12R13; R1 es H o alquilo C1-C7; R2 es H, CN, entre otros; R3 es H, alquilo C1-C7 o cicloalquilo C3-C8; R12 es heterocicloalquilo opcionalmente sustituido y que comprende un atomo de N; R13 es H, alquilo C1-C7 o cicloalquilo C3-C8. Son compuestos preferidos: 2-(2-metilimidazo[1,2-b]piridazin-6-il)-7-(4-metilpiperazin-1-il)pirido[1,2-a]pirimidin-4-ona; 7-[(8aR)-3,4,6,7,8,8a-hexahidro-1H-pirrolo[1,2-a]pirazin-2-il]-2-(2-metilimidazo[1,2-b]piridazin-6-il)pirido[1,2-a]pirimidin-4-ona; entre otros. Tambien se refiere a un proceso, composiciones farmaceuticas y un metodo. Dichos compuestos son moduladores de empalme genico de supervivencia de neuronas motoras (SMN2) siendo utiles en el tratamiento de la atrofia muscular espinal (AME)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461993839P | 2014-05-15 | 2014-05-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20170128A1 true PE20170128A1 (es) | 2017-03-16 |
Family
ID=53175048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016002128A PE20170128A1 (es) | 2014-05-15 | 2015-05-11 | Compuestos para tratar atrofia muscular espinal |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US9969754B2 (es) |
| EP (3) | EP3663296B1 (es) |
| JP (1) | JP6236173B2 (es) |
| KR (2) | KR102213740B1 (es) |
| CN (1) | CN106459092B (es) |
| AR (2) | AR100442A1 (es) |
| AU (1) | AU2015261046C1 (es) |
| BR (1) | BR112016026205B1 (es) |
| CA (1) | CA2948561C (es) |
| CL (1) | CL2016002836A1 (es) |
| CR (1) | CR20160518A (es) |
| DK (1) | DK3143025T3 (es) |
| EA (2) | EA035068B1 (es) |
| ES (2) | ES2949660T3 (es) |
| FR (1) | FR21C1039I2 (es) |
| HR (2) | HRP20230637T1 (es) |
| HU (2) | HUE046491T2 (es) |
| IL (2) | IL248653B (es) |
| LT (1) | LTC3143025I2 (es) |
| MA (2) | MA39995B1 (es) |
| MX (1) | MX371050B (es) |
| MY (1) | MY174284A (es) |
| NL (1) | NL301128I2 (es) |
| NO (2) | NO2021035I1 (es) |
| NZ (1) | NZ725008A (es) |
| PE (1) | PE20170128A1 (es) |
| PH (1) | PH12016502081B1 (es) |
| PL (2) | PL3663296T3 (es) |
| PT (1) | PT3143025T (es) |
| RS (1) | RS59718B1 (es) |
| SG (1) | SG11201609497TA (es) |
| SI (2) | SI3663296T1 (es) |
| TW (1) | TWI667239B (es) |
| UA (1) | UA119670C2 (es) |
| WO (1) | WO2015173181A1 (es) |
| ZA (1) | ZA201607026B (es) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2697174T3 (es) | 2012-02-10 | 2019-01-22 | Ptc Therapeutics Inc | Compuestos para tratar atrofia muscular espinal |
| CN105392790B (zh) | 2013-08-19 | 2019-04-19 | 豪夫迈·罗氏有限公司 | 4H-吡啶并[1,2-a]嘧啶-4-酮化合物制备用于预防或治疗癌症的药物的用途 |
| US10882868B2 (en) * | 2014-05-15 | 2021-01-05 | Hoffmann-La Roche Inc. | Compounds for treating spinal muscular atrophy |
| JP6749343B2 (ja) | 2015-05-20 | 2020-09-02 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 脊髄性筋萎縮症を処置するための化合物 |
| US10668171B2 (en) | 2015-05-30 | 2020-06-02 | Ptc Therapeutics, Inc. | Methods for modulating RNA splicing |
| AU2016353961B2 (en) * | 2015-11-12 | 2019-08-29 | F. Hoffmann-La Roche Ag | Compositions for treating spinal muscular atrophy |
| CN108137601A (zh) * | 2015-11-12 | 2018-06-08 | 豪夫迈·罗氏有限公司 | 用于治疗肌萎缩性侧索硬化症的化合物 |
| WO2017097728A1 (en) | 2015-12-10 | 2017-06-15 | F. Hoffmann-La Roche Ag | Bridged piperidine derivatives |
| KR20220100719A (ko) | 2015-12-10 | 2022-07-15 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료 또는 개선을 위한 조성물 |
| CA3043755A1 (en) * | 2016-11-28 | 2018-05-31 | Ptc Therapeutics, Inc. | Methods for modulating rna splicing |
| AU2018282154B2 (en) | 2017-06-05 | 2022-04-07 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
| KR20200017476A (ko) | 2017-06-14 | 2020-02-18 | 피티씨 테라퓨틱스, 인크. | Rna 스플라이싱의 변경 방법 |
| WO2019005993A1 (en) | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | METHODS OF TREATING HUNTINGTON'S DISEASE |
| CA3067591A1 (en) | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | Methods for treating huntington's disease |
| KR20200058468A (ko) * | 2017-09-22 | 2020-05-27 | 에프. 호프만-라 로슈 아게 | 7-(4,7-다이아자스피로[2.5]옥탄-7-일)-2-(2,8-다이메틸이미다조[1,2-b]피리다진-6-일)피리도[1,2-a]피리미딘-4-온 유도체의 제조 방법 |
| CN111182900A (zh) * | 2017-10-03 | 2020-05-19 | 豪夫迈·罗氏有限公司 | Sma的新疗法 |
| AU2019243048A1 (en) | 2018-03-27 | 2020-10-15 | Ptc Therapeutics, Inc. | Compounds for treating Huntington's disease |
| BR112020026534A2 (pt) | 2018-06-27 | 2021-03-23 | Ptc Therapeutics, Inc. | Compostos de heteroarila para o tratamento da doença de huntington |
| CA3105174A1 (en) | 2018-06-27 | 2020-01-02 | Reborna Biosciences, Inc. | Prophylactic or therapeutic agent for spinal muscular atrophy |
| WO2020005882A1 (en) | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| IL279688B2 (en) | 2018-06-27 | 2025-01-01 | Ptc Therapeutics Inc | Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease |
| KR102705600B1 (ko) | 2018-10-19 | 2024-09-12 | 에프. 호프만-라 로슈 아게 | 피리도[1,2-a]피리미딘-4-온 유도체의 형태, 그의 제형 및 그의 제조 방법 |
| CN114245794B (zh) | 2019-05-13 | 2024-09-13 | Ptc医疗公司 | 用于治疗亨廷顿氏病的化合物 |
| JP2022536669A (ja) | 2019-06-12 | 2022-08-18 | エフ．ホフマン－ラ ロシュ アーゲー | Ｓｍａの新規治療 |
| WO2021021775A1 (en) | 2019-07-31 | 2021-02-04 | Teva Pharmaceuticals International Gmbh | Solid state forms of risdiplam and process for preparation thereof |
| KR20230004575A (ko) * | 2020-04-08 | 2023-01-06 | 레믹스 테라퓨틱스 인크. | 스플라이싱을 조절하기 위한 화합물 및 방법 |
| WO2022048675A1 (zh) * | 2020-09-07 | 2022-03-10 | 苏州科睿思制药有限公司 | Risdiplam晶型及其制备方法和用途 |
| WO2022162107A1 (en) | 2021-02-01 | 2022-08-04 | Sandoz Ag | Crystalline form of risdiplam |
| EP4308577B1 (en) * | 2021-03-17 | 2024-12-25 | F. Hoffmann-La Roche AG | New thiadiazolopyrimidone derivatives |
| IL305203A (en) | 2021-03-17 | 2023-10-01 | Hoffmann La Roche | New histories of thiazolopyrimidines |
| EP4308572B1 (en) * | 2021-03-17 | 2025-04-23 | F. Hoffmann-La Roche AG | New thienopyrimidinone derivatives |
| AU2022237836B2 (en) * | 2021-03-18 | 2024-07-04 | F. Hoffmann-La Roche Ag | Process for preparing risdiplam |
| WO2023057404A1 (en) | 2021-10-06 | 2023-04-13 | F. Hoffmann-La Roche Ag | Novel combined administration |
| WO2023202501A1 (zh) * | 2022-04-18 | 2023-10-26 | 深圳市塔吉瑞生物医药有限公司 | 取代的吡啶并嘧啶酮类化合物及包含该化合物的组合物及其用途 |
| WO2023240236A1 (en) | 2022-06-10 | 2023-12-14 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of spinal muscular atrophy related disorders |
| WO2024069646A1 (en) * | 2022-09-26 | 2024-04-04 | Natco Pharma Limited | Improved process for the preparation of risdiplam and its intermediates |
| JP2025534681A (ja) | 2022-10-14 | 2025-10-17 | ジェネンテック， インコーポレイテッド | 脊髄性筋萎縮症の治療方法 |
| IL322038A (en) * | 2023-01-21 | 2025-09-01 | Harman Finochem Ltd | Process for preparing risdiplam, new intermediates, and process for preparing them |
| CN121219298A (zh) | 2023-04-20 | 2025-12-26 | 豪夫迈·罗氏有限公司 | 噻吩并[3,2-b]吡啶衍生物 |
| AU2024286618A1 (en) | 2023-06-09 | 2025-10-30 | F. Hoffmann-La Roche Ag | Inducible gene expression system |
| CN117050096A (zh) * | 2023-07-17 | 2023-11-14 | 杭州诺澳生物医药科技有限公司 | 一种利司扑兰的制备方法 |
| US20250144031A1 (en) | 2023-10-27 | 2025-05-08 | Hoffmann-La Roche Inc. | Composition for treating spinal muscular atrophy |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ333727A (en) * | 1996-08-06 | 2000-09-29 | Pfizer | Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic arylsulfonylamino hydroxamic acid derivatives |
| EP2573080A1 (en) | 2007-09-27 | 2013-03-27 | The United States of America, as Represented by the Secretary, Department of Health and Human Services | Isoindoline compounds for the treatment of spinal muscular atrophy and other uses |
| WO2009151546A2 (en) * | 2008-05-27 | 2009-12-17 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
| KR20100012134A (ko) * | 2008-07-28 | 2010-02-08 | 신호열 | 마우스 |
| US8986935B2 (en) | 2008-08-13 | 2015-03-24 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
| WO2010019326A1 (en) * | 2008-08-14 | 2010-02-18 | Cardiac Pacemakers, Inc. | Performance assessment and adaptation of an acoustic communication link |
| JP6193881B2 (ja) * | 2011-12-30 | 2017-09-06 | ピーティーシー セラピューティクス， インコーポレイテッド | 脊髄性筋萎縮症を治療するための化合物 |
| CA2862084C (en) * | 2012-01-26 | 2021-05-11 | Ptc Therapeutics, Inc. | 1h-isochromen-1-one derivatives and compositions thereof for treating spinal muscular atrophy |
| ES2697174T3 (es) | 2012-02-10 | 2019-01-22 | Ptc Therapeutics Inc | Compuestos para tratar atrofia muscular espinal |
| WO2014012050A2 (en) | 2012-07-13 | 2014-01-16 | Indiana University Research & Technology Corporation | Compounds for treatment of spinal muscular atrophy |
| AU2016353961B2 (en) | 2015-11-12 | 2019-08-29 | F. Hoffmann-La Roche Ag | Compositions for treating spinal muscular atrophy |
-
2015
- 2015-05-11 DK DK15721701T patent/DK3143025T3/da active
- 2015-05-11 PL PL19200058.6T patent/PL3663296T3/pl unknown
- 2015-05-11 EA EA201692280A patent/EA035068B1/ru active Protection Beyond IP Right Term
- 2015-05-11 MA MA39995A patent/MA39995B1/fr unknown
- 2015-05-11 JP JP2016567816A patent/JP6236173B2/ja active Active
- 2015-05-11 SI SI201531952T patent/SI3663296T1/sl unknown
- 2015-05-11 PL PL15721701T patent/PL3143025T3/pl unknown
- 2015-05-11 CR CR20160518A patent/CR20160518A/es unknown
- 2015-05-11 RS RS20191541A patent/RS59718B1/sr unknown
- 2015-05-11 CA CA2948561A patent/CA2948561C/en active Active
- 2015-05-11 MX MX2016014547A patent/MX371050B/es active IP Right Grant
- 2015-05-11 EP EP19200058.6A patent/EP3663296B1/en active Active
- 2015-05-11 EA EA202090486A patent/EA202090486A3/ru unknown
- 2015-05-11 ES ES19200058T patent/ES2949660T3/es active Active
- 2015-05-11 KR KR1020167034983A patent/KR102213740B1/ko active Active
- 2015-05-11 ES ES15721701T patent/ES2761423T3/es active Active
- 2015-05-11 HR HRP20230637TT patent/HRP20230637T1/hr unknown
- 2015-05-11 EP EP23169721.0A patent/EP4241772A3/en not_active Withdrawn
- 2015-05-11 SI SI201531021T patent/SI3143025T1/sl unknown
- 2015-05-11 HR HRP20192159TT patent/HRP20192159T1/hr unknown
- 2015-05-11 CN CN201580027306.9A patent/CN106459092B/zh active Active
- 2015-05-11 AU AU2015261046A patent/AU2015261046C1/en active Active
- 2015-05-11 SG SG11201609497TA patent/SG11201609497TA/en unknown
- 2015-05-11 HU HUE15721701A patent/HUE046491T2/hu unknown
- 2015-05-11 WO PCT/EP2015/060343 patent/WO2015173181A1/en not_active Ceased
- 2015-05-11 PE PE2016002128A patent/PE20170128A1/es unknown
- 2015-05-11 UA UAA201612716A patent/UA119670C2/uk unknown
- 2015-05-11 EP EP15721701.9A patent/EP3143025B1/en active Active
- 2015-05-11 NZ NZ72500815A patent/NZ725008A/en unknown
- 2015-05-11 PT PT157217019T patent/PT3143025T/pt unknown
- 2015-05-11 BR BR112016026205-0A patent/BR112016026205B1/pt active IP Right Grant
- 2015-05-11 MA MA051988A patent/MA51988A/fr unknown
- 2015-05-11 KR KR1020217002966A patent/KR102256013B1/ko active Active
- 2015-05-11 MY MYPI2016001903A patent/MY174284A/en unknown
- 2015-05-11 PH PH1/2016/502081A patent/PH12016502081B1/en unknown
- 2015-05-14 TW TW104115433A patent/TWI667239B/zh active
- 2015-05-14 AR ARP150101500A patent/AR100442A1/es not_active Application Discontinuation
-
2016
- 2016-10-12 ZA ZA2016/07026A patent/ZA201607026B/en unknown
- 2016-10-31 IL IL24865316A patent/IL248653B/en active IP Right Grant
- 2016-11-08 CL CL2016002836A patent/CL2016002836A1/es unknown
- 2016-11-14 US US15/351,267 patent/US9969754B2/en active Active
-
2019
- 2019-10-17 IL IL270027A patent/IL270027B/en active IP Right Grant
-
2021
- 2021-09-09 FR FR21C1039C patent/FR21C1039I2/fr active Active
- 2021-09-10 NO NO2021035C patent/NO2021035I1/no unknown
- 2021-09-14 HU HUS2100037C patent/HUS2100037I1/hu unknown
- 2021-09-14 LT LTPA2021010C patent/LTC3143025I2/lt unknown
- 2021-09-15 NL NL301128C patent/NL301128I2/nl unknown
-
2023
- 2023-12-01 AR ARP230103289A patent/AR131260A2/es unknown
-
2025
- 2025-08-14 NO NO2025038C patent/NO2025038I1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR131260A2 (es) | Compuestos para tratar atrofia muscular espinal | |
| CY1125460T1 (el) | Ενωσεις ιμιδαζο [4,5-d]πυρρολο [2,3-β]πυριδινης ως αναστολεις κινασων janus | |
| JOP20190144A1 (ar) | إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز | |
| PE20171307A1 (es) | Compuestos de triazolopirimidina y usos de los mismos | |
| EA202090659A1 (ru) | СОСТАВЫ, СОДЕРЖАЩИЕ 6-(2-ГИДРОКСИ-2-МЕТИЛПРОПОКСИ)-4-(6-(6-((6-МЕТОКСИПИРИДИН-3-ИЛ)МЕТИЛ)-3,6-ДИАЗАБИЦИКЛО[3.1.1]ГЕПТАН-3-ИЛ)ПИРИДИН-3-ИЛ)ПИРАЗОЛО[1,5-a]ПИРИДИН-3-КАРБОНИТРИЛ | |
| MX383823B (es) | Macrociclos de diarilo quirales y usos de los mismo. | |
| PE20160588A1 (es) | Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos | |
| GT201300291A (es) | Derivados de piridin-2(1h)-ona útiles como medicamentos para el tratamiento de trastornos mieloproliferativos, rechazo de trasplantes, enfermedades mediadas por el sistema inmune y enfermedades inflamatorias. | |
| PE20190811A1 (es) | Derivados de pirazolopirimidinas como inhibidor de quinasa | |
| PE20230731A1 (es) | Compuestos heterociclicos como inmunomoduladores | |
| MX379425B (es) | 7-bencil-4-(2-metilbencilo) -2,4,6,7,8,9-hexahidroimidazo [1,2-a] pirido [3,4-e] pirimidin-5 (1h) -ona, análogos y sales del mismo y su uso en terapia. | |
| EA201991109A1 (ru) | ПРОИЗВОДНЫЕ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2 | |
| MX2015009950A (es) | Compuestos de imidazopiridina y sus usos. | |
| PE20141023A1 (es) | Derivados de (1,2,4) triazolo [4,3-a] quinoxalina como inhibidores de fosfodiesterasas | |
| ECSP19043790A (es) | Pirazolo[3,4-b]piridinas e imidazo[1,5-b]piridazinas como inhibidores de PDE1 | |
| PE20150754A1 (es) | Derivados de azaindol que actuan como inhibidores de pi 3k | |
| PE20171104A1 (es) | Pirazolpiridinaminas como inhibidores de mknk1 y mknk2 | |
| UY35419A (es) | Inhibidores de cdk9 quinasa de pirrolo (2,3- b) piridina | |
| NI202000100A (es) | Inhibidores de moléculas pequeñas de la familia de quinasa jak | |
| EA201991094A1 (ru) | СОЕДИНЕНИЯ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2 | |
| CL2017000223A1 (es) | [1,2,4]triazolo[4,3-b]piridazinas para su uso en el tratamiento de enfermedades proliferativas | |
| BR112015000459A2 (pt) | inibidores da enzima fosfodiesterase 10 | |
| PE20150965A1 (es) | Azaindolinas | |
| EA201990973A1 (ru) | СОЕДИНЕНИЯ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2 | |
| UA110245C2 (xx) | ПОХІДНІ 7-(ГЕТЕРОАРИЛАМІНО)-6,7,8,9-ТЕТРАГІДРОПІРИДО$1,2-а]ІНДОЛ-ОЦТОВОЇ КИСЛОТИ ТА ЇХ ЗАСТОСУВАННЯ ЯК МОДУЛЯТОРІВ РЕЦЕПТОРА ПРОСТАГЛАНДИНУ D2 |